What Are Wall Street Analysts' Target Price for Bio-Techne Stock?

Core Insights - Bio-Techne Corporation (TECH) is a Minnesota-based company focused on developing, manufacturing, and selling life science reagents, instruments, and services, with a market capitalization of $10.1 billion [1] Performance Overview - Over the past 52 weeks, TECH shares have declined by 7.7%, underperforming the S&P 500 Index, which increased by 14.4%. However, year-to-date, TECH's stock is up 7.3%, outperforming the S&P 500's 1.4% increase [2] - TECH has also underperformed the iShares Biotechnology ETF (IBB), which rose by 27.2% over the past 52 weeks, but has outperformed IBB's year-to-date rise of 1.2% [3] Earnings Performance - On February 4, TECH shares surged by 6.3% following better-than-expected Q2 earnings results, with net sales growing to $295.9 million, exceeding consensus estimates by 1.3%. The adjusted operating margin expanded by 100 basis points year-over-year, and adjusted EPS increased by 9.5% to $0.46, surpassing analyst expectations of $0.43 [6] Future Earnings Expectations - For fiscal 2026, analysts expect TECH's EPS to remain stable at $1.71 year-over-year. The company has a strong earnings surprise history, exceeding consensus estimates in the last four quarters. The consensus rating among 15 analysts is a "Moderate Buy," with 10 "Strong Buy" and five "Hold" ratings [7] Analyst Ratings and Price Targets - The configuration of analyst ratings has become more bullish, with one analyst suggesting a "Strong Sell" rating. On February 6, Wells Fargo analyst maintained a "Buy" rating on TECH with a price target of $76, indicating an 18.8% potential upside. The mean price target of $74.67 represents a 16.7% premium, while the highest price target of $80 suggests a 25.1% potential upside [8]